Published in Clin Infect Dis on July 24, 2002
Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev (2003) 4.14
Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun (2003) 1.33
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
"To BCG or not to BCG, that is the question!". The challenge of BCG vaccination: Why can't we get it right? Paediatr Child Health (2003) 0.91
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis (2006) 0.81
Cloning of HBsAg-encoded genes in different vectors and their expression in eukaryotic cells. World J Gastroenterol (2003) 0.78
Epidemiology of Tuberculosis in Malawi. Malawi Med J (2006) 0.76
TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals. PLoS One (2016) 0.75
Tuberculous Psoas Abscess and Worsening Vascular Aneurysm; All from Bacillus Calmette-Guerin (BCG) Therapy? Am J Case Rep (2017) 0.75
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine (2006) 1.48
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 1.37
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis (2010) 1.00
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes. Infect Immun (2002) 0.91
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Chlamydia pneumoniae infection in IL-10 knock out mice: accelerated clearance but severe pulmonary inflammatory response. Microb Pathog (2008) 0.85
Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine (2004) 0.83
Gene expression signatures characterizing the development of lymphocyte response during experimental Chlamydia pneumoniae infection. Microb Pathog (2009) 0.82
DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine (2004) 0.82
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis (2006) 0.81
Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model. Clin Diagn Lab Immunol (2003) 0.80
Up-regulation of host cell genes during interferon-gamma-induced persistent Chlamydia pneumoniae infection in HL cells. J Infect Dis (2006) 0.76
Systemic and mucosal antibody response in experimental Chlamydia pneumoniae infection of mice. Comp Med (2006) 0.75